Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Active, not recruiting · NCT06106295 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cushing syndrome, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, Urogenital Abnormalities, Urogenital Diseases, adrenal gland disorder, adrenal gland hyperfunction, adrenogenital syndrome, congenital adrenal hyperplasia, disorder of sexual differentiation, ectopic ACTH secretion syndrome, endocrine system disorder, gonadal disorder, hereditary disease, inborn errors of metabolism, metabolic disease, neoplasm, paraneoplastic syndrome, steroid inherited metabolic disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT06106295 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic Minnesota | Rochester | United States | 40 |